Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; Zentren für seelische Gesundheit, BBRZ-Med, Vienna, Austria; Faculty of Medicine, Sigmund Freud University, Freudplatz 3, Vienna 1020, Austria; Arbeitsgemeinschaft für Verhaltensmodifikation, Salzburg, Austria.
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; Zentren für seelische Gesundheit, BBRZ-Med, Vienna, Austria.
Eur Neuropsychopharmacol. 2022 May;58:103-108. doi: 10.1016/j.euroneuro.2022.03.005. Epub 2022 Apr 20.
Genetic factors were shown to play a major role in both variation of treatment response and incidence of adverse effects to medication in affective disorders. Nevertheless, there is still a lack of therapygenetic studies, investigating the prediction of psychological therapy outcomes from genetic markers. Neuroplasticity and one of its mediators, brain-derived neurotrophic factor (BDNF), are potential research targets in this field. We aimed to investigate Tag SNP polymorphisms of the BDNF gene in depressed patients treated with cognitive behavioral therapy (CBT) in the context of a standardized 6-weeks outpatient rehabilitation program. Treatment response was assessed calculating the mean differences in BDI-II (Beck Depression Inventory) scores from admission to discharge. Six BDNF SNPs, including the Val66Met polymorphism (rs6265), were genotyped. Both genotypic data and BDI-II-scores at admission and discharge were available for 277 patients. Three SNPs, rs10501087 (p = 0.005, FDRp=0.015), rs11030104 (p = 0.006, FDRp=0.012), and the Val66Met polymorphism (rs6265, p<0.001, FDRp=0.006), were significantly associated with treatment response in depressed patients, even after multiple testing correction using the false discovery rate method (FDRp). We conclude that BDNF might serve as promising genetic marker for treatment response to psychological treatment in depression. However, due to our limited sample size, further studies are needed to disentangle the role of BDNF as potential therapygenetic marker.
遗传因素被证明在情感障碍的治疗反应变异和药物不良反应的发生率中都起着重要作用。然而，在治疗遗传学研究中，仍然缺乏针对从遗传标记预测心理治疗结果的研究。神经可塑性及其介导物脑源性神经营养因子 (BDNF) 是该领域的潜在研究目标。我们旨在研究接受认知行为治疗 (CBT) 的抑郁症患者中 BDNF 基因的 Tag SNP 多态性，该治疗是在标准化的 6 周门诊康复计划中进行的。治疗反应通过计算从入院到出院 Beck 抑郁量表 (BDI-II) 评分的均值差异来评估。共检测了 6 个 BDNF SNPs，包括 Val66Met 多态性（rs6265）。对 277 名患者进行了基因分型数据和入院及出院时的 BDI-II 评分检测。有三个 SNP，rs10501087(p=0.005, FDRp=0.015)、rs11030104(p=0.006, FDRp=0.012)和 Val66Met 多态性(rs6265,p<0.001, FDRp=0.006)与抑郁症患者的治疗反应显著相关，即使在使用错误发现率方法 (FDRp) 进行多次测试校正后也是如此。我们的结论是，BDNF 可能是抑郁症患者对心理治疗反应的有前途的遗传标志物。然而，由于我们的样本量有限，需要进一步的研究来阐明 BDNF 作为潜在治疗遗传学标志物的作用。
